<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="171967">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00857597</url>
  </required_header>
  <id_info>
    <org_study_id>D00668-01C</org_study_id>
    <nct_id>NCT00857597</nct_id>
  </id_info>
  <brief_title>Endoscopic Fundoplication Versus Proton Pump Inhibitors for GERD Treatment</brief_title>
  <acronym>TvP</acronym>
  <official_title>A Randomized Controlled Trial of Transoral Incisionless Fundoplication (TIF) Versus Proton Pump Inhibitors (PPIs) for Treatment of GERD: The TIF vs. PPIs Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EndoGastric Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sandhill Scientific</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Crospon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to evaluate the relative merits, safety and effectiveness of
      Transoral Incisionless Fundoplication (TIF) in GERD patients currently treated with daily
      Proton Pump Inhibitors (PPIs).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">March 2011</completion_date>
  <primary_completion_date type="Anticipated">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GERD symptoms</measure>
    <time_frame>at 0, 6 and 12 month follow- up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PPI usage</measure>
    <time_frame>at 0, 6 and 12 month follow- up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lower esophageal acid exposure</measure>
    <time_frame>at 0, 6 and 12 month follow- up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healed reflux esophagitis</measure>
    <time_frame>at 0, 6 and 12 month follow- up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events</measure>
    <time_frame>at 0, 6 and 12 month follow- up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Gastroesophageal Reflux Disease (GERD)</condition>
  <arm_group>
    <arm_group_label>EsophyX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Proton Pump Inhibitors</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transoral Incisionless Fundoplication</intervention_name>
    <description>The TIF procedure using the EsophyX system with SerosaFuse fasteners was designed to create full-thickness serosa-to-serosa plications and construct valves of 3-5 cm in length and 200-300Â° in circumference.</description>
    <arm_group_label>EsophyX</arm_group_label>
    <other_name>TIF procedure</other_name>
    <other_name>ELF procedure</other_name>
    <other_name>Endoluminal fundoplication</other_name>
    <other_name>Endoscopic fundoplication</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proton Pump Inhibitors; active control</intervention_name>
    <description>Proton Pump Inhibitors; active control</description>
    <arm_group_label>Proton Pump Inhibitors</arm_group_label>
    <other_name>Esomeprazole</other_name>
    <other_name>Lansomeprazole</other_name>
    <other_name>Omeprazole</other_name>
    <other_name>Pantoprazole</other_name>
    <other_name>Rabeprazole</other_name>
    <other_name>Nexium</other_name>
    <other_name>Prevacid</other_name>
    <other_name>Dakar</other_name>
    <other_name>Lanso</other_name>
    <other_name>Lanzor</other_name>
    <other_name>Prezal</other_name>
    <other_name>Lanzol</other_name>
    <other_name>Prilosec</other_name>
    <other_name>Losec</other_name>
    <other_name>Logastric</other_name>
    <other_name>Protonix</other_name>
    <other_name>Zurcal</other_name>
    <other_name>Pantozol</other_name>
    <other_name>Zurcale</other_name>
    <other_name>Aciphex</other_name>
    <other_name>Pariet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-75 years

          -  Proven gastroesophageal reflux (pH &lt; 4 for &gt; 4.3% time while off PPIs for 7-14 days)

          -  On daily PPIs for &gt; 1 year

          -  Recurrence of GERD symptoms (GERD-HRQL score difference of &gt; 10 between on and off
             PPIs)

          -  Normal or hypotonic LES resting pressure (5-40 mmHg)

          -  Patient willingness to cooperate with random group assignment, attend 4-5 office
             visits and comply with all tests in this protocol

          -  Signed informed consent

        Exclusion Criteria:

          -  BMI &gt; 35

          -  Hiatal hernia &gt; 2 cm

          -  Esophagitis grade D

          -  Barrett's esophagus

          -  Esophageal stricture

          -  Esophageal ulcer

          -  Esophageal motility disorder

          -  Gastric motility disorder

          -  Prior splenectomy

          -  Gastric paralysis

          -  Pregnancy (in females)

          -  Immunosuppression

          -  ASA &gt; 2

          -  Portal hypertension

          -  Coagulation disorders

          -  Previous antireflux procedure

          -  Any other health condition, which the investigator believes would prevent the patient
             from completing the study

          -  Lack of fluency in English
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Blair A Jobe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicole D Bouvy, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Maastricht, The Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blair A Jobe, MD</last_name>
      <phone>412-623-2025</phone>
      <email>jobeba@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Bart PL Witteman, MD</last_name>
      <phone>412-623-3073</phone>
      <email>bplwitteman@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Blair A Jobe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Maastricht</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole D Bouvy, MD, PhD</last_name>
      <phone>+31433876543</phone>
      <phone_ext>6883</phone_ext>
      <email>n.bouvy@mumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Bart PL Witteman, MD</last_name>
      <phone>+31433876543</phone>
      <email>bplwitteman@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nicole D Bouvy, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <lastchanged_date>April 17, 2009</lastchanged_date>
  <firstreceived_date>March 4, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Blair A Jobe, MD</name_title>
    <organization>University of Pittsburgh Medical Center</organization>
  </responsible_party>
  <keyword>GERD</keyword>
  <keyword>endoscopic</keyword>
  <keyword>fundoplication</keyword>
  <keyword>Proton Pump Inhibitors</keyword>
  <keyword>heartburn</keyword>
  <keyword>anti-reflux surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Proton Pump Inhibitors</mesh_term>
    <mesh_term>Pantoprazole</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
